

Attorney Docket No.: RTS-0245  
Inventors: Monia and Cowser  
Serial No.: 09/920,677  
Filing Date: August 1, 2001  
Page 2

The following listing of claims will replace all prior versions and listings of claims in this application.

**Listing of Claims:**

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a start codon region, nucleobases 46 through 1050 or nucleobases 1214 through 1545 of a coding region, nucleobases 1591 through 1609 of a stop codon region, or nucleobases 1797 through 2341 of a 3'-untranslated region of a nucleic acid molecule encoding p70 S6 kinase (SEQ ID NO: 3), wherein said compound specifically hybridizes with one of said regions and inhibits the expression of p70 S6 kinase.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claims 3-4 (previously canceled).

Claim 5 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 6 (original): The compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 7 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Attorney Docket No.: RTS-0245  
Inventors: Monia and Cowser  
Serial No.: 09/920,677  
Filing Date: August 1, 2001  
Page 3

Claim 8 (original): The compound of claim 7 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 9 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 10 (original): The compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

Claim 11 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 12 (canceled).

Claim 13 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 14 (original): The composition of claim 13 further comprising a colloidal dispersion system.

Claim 15 (original): The composition of claim 13 wherein the compound is an antisense oligonucleotide.

Claim 16 (currently amended): A method of inhibiting the expression of p70 S6 kinase in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of p70 S6 kinase is inhibited.

Claims 17-20 (canceled).